Why Clinical Data Platforms Will Decide Who Wins in RWE
- Life sciences and health systems face over $168 billion in combined opportunity risk across biopharma and health systems if they fail to meet rising consumer expectations.
- Approximately one-third of organizations have begun scaling AI beyond pilots, and just 1% of companies describe their AI deployment as fully mature – leaving most RWE programs stuck in experimentation.
- Only 6% of executives say they are very capable of withstanding cyber attacks across all vulnerabilities, even as clinical data footprints expand.
- Leaders are shifting from one-off RWE studies to unified clinical data platforms for real-world evidence – built on cloud, governed architectures, and managed services.
The gap between R&D data and real-world evidence is not a science problem. It is a systems and governance problem.
Deloitte estimates over $168 billion in combined opportunity risk across biopharma and health systems for organizations that fail to adapt to consumer-driven expectations around health. Much of that risk lives in how slowly insights travel from R&D to regulatory, commercial, and payer decisions.
Technology is not the constraint. Most life sciences enterprises already use AI – but McKinsey finds only about one-third of organizations have begun scaling AI beyond pilots. The pattern in real-world evidence programs looks identical: strong experimentation, weak platformization.
This guide breaks down what FDA-grade RWE actually demands from your data stack, how to choose the right architecture, how to structure a build-vs-outsource decision, and how to secure and staff these platforms over the next three to five years.
What FDA-Grade Real-World Evidence Requires From Your Data Stack
The FDA is specific: RWE is only as credible as the real-world data behind it. Guidance on EHRs, registries, and claims data consistently stresses relevance, reliability, and transparent analytical methods.
That translates into concrete platform requirements for CIOs. You need a regulatory-grade RWD pipeline with documented lineage, fit-for-purpose curation, and governed access. A data lake and a few notebooks do not meet that bar.
Forrester identifies governance and integration as the top barriers to deriving value from data. That is precisely why most RWE programs stall at the proof-of-concept stage. A solid data governance and compliance framework is not a back-office requirement – it is the foundation your RWE rests on.
Consider a mid-size biopharma preparing a label expansion submission. Their clinical trial data sits in one system, patient registry data in another, and EHR-sourced claims in a third. Without harmonized lineage and standardized access controls, the evidence package takes months to assemble – and still faces questions from regulators on data provenance. That delay is entirely due to a platform and governance gap, not a scientific failure. Addressing it begins by bridging the healthcare data gap at the architectural level.
From Pilots to Platforms: Building the Business Case for RWE-Ready Clinical Data
Just 1% of companies describe their AI deployment as fully mature. RWE programs follow the same curve – well-funded pilots, limited reuse, and no shared infrastructure.
For CFOs, the case is straightforward. Funding five isolated RWE studies a year costs more – in data preparation, vendor coordination, and delayed submissions – than building a shared data intelligence platform for governed analytics that each study can draw on.
The investment narrative should focus on three value cases:
- Faster regulatory submissions with pre-built, audit-ready data pipelines
- Label expansion and lifecycle management supported by reusable RWE assets
- Better payer negotiations grounded in evidence already structured for HEOR
A scalable, compliant cloud foundation is what makes these cases durable – not a series of bespoke projects.
What Is the Right Architecture for a Clinical Data Platform That Supports Both R&D and Real-World Evidence?
Warehouses are structured and governed, but rigid. Data lakes are flexible but difficult to govern for regulatory quality. A life sciences clinical data lakehouse gives you both: schema-on-read flexibility for multi-modal data, decoupled storage and compute for AI workloads, and enforced standards and semantic layers that make outputs trustworthy.
Research comparing clinical data warehouses, lakes, and lakehouses in healthcare settings confirms that lakehouses perform best when AI, cross-domain analytics, and regulatory rigor need to coexist in the same environment.
The key decision for CIOs: separate platforms for clinical trials and real-world data create duplication, inconsistent standards, and governance debt. A unified platform with domain-specific zones – trial data, RWD, HEOR outputs – is almost always the better long-term choice. Pair it with AI-ready cloud infrastructure, and you have the foundation to scale evidence generation, not just execute individual studies.
Build, Buy, or Partner: How Much of Your RWE Capability Should You Outsource?
Most RWE work today is fragmented across CROs, SaaS tools, and internal teams. That creates inconsistent methods, duplicated data preparation, and poor reuse – all of which inflate cost and slow decisions.
A practical model: keep the core platform, governance layer, and critical analytical models in-house. Use managed clinical data platform services and specialist CROs for variable demand, complex methods, and country-specific requirements.
When evaluating partners, go beyond features. Ask about:
- Data ownership and lineage - who controls provenance records after the engagement ends
- Interoperability - how the partner’s outputs connect with your internal platform standards
- Incident response - what happens to your RWD if there is a breach or service outage
- Regulatory alignment - how they stay current with evolving FDA RWE guidance
Reviewing real-world impact stories across data, cloud, and AI from prospective partners is a good starting point for due diligence.
Securing High-Value Clinical Data: Cyber Resilience for RWE Platforms
PwC’s 2026 Global Digital Trust Insights found that only 6% of executives say they are very capable of withstanding cyber-attacks across all vulnerabilities. Clinical data platforms – consolidating R&D, patient, and genomic data in a single environment – are high-value targets.
The right posture is to design for cyber resilience from day one, not retrofit it after deployment. That means zero-trust identity, encryption at rest and in transit, continuous monitoring, and third-party risk controls baked into the platform architecture.
For organizations that cannot staff 24/7 coverage internally, integrated cyber resilience capabilities and data protection for regulated workloads are the practical answer – not optional additions.
Talent and Operating Models: How Clinical Data Platforms Change the Work
A clinical data platform decision is equally an operating model decision. CIOs and COOs should plan for three shifts:
- Data product ownership - assign accountable owners to key RWE data assets, with defined SLAs and quality standards
- Cross-functional governance - a joint R&D–IT steering group that connects biostatistics, HEOR, engineering, and compliance
- Structured upskilling - invest in retraining existing CDM and bio stat teams on new platforms rather than defaulting to replacement hiring
Modernizing knowledge and data operations is as much about people and process as it is about technology. Platforms designed with a people-first engineering mindset consistently see faster adoption and fewer governance failures.
Ready to Move From RWE Pilots to a Platform That Lasts?
Waiting for perfect regulatory clarity or a flawless vendor before acting is itself a risk. The organizations building durable RWE capabilities right now are not the ones with the most sophisticated tools – they are the ones that paired governance with architecture from the start, treated RWE as a platform investment, and chose partners accountable for long-term outcomes.
If you want to explore what this could look like for your environment, talk to our team about your current clinical data challenges, and we will help you outline a roadmap for R&D data modernization. You can also reach us directly at inquiries@scalence.com.
FAQ
What ROI should executives expect from investing in an RWE-ready clinical data platform?
The clearest returns come from reduced data preparation time per study, faster regulatory submissions, and reusable evidence assets for label expansion and payer negotiations. Shared platforms typically lower per-study costs over a three-to-five-year horizon compared to funding isolated RWE projects.
How can we tell if our real-world data is fit for purpose for regulatory and payer decisions, not just for internal dashboards?
FDA guidance is explicit: fit-for-purpose RWD must demonstrate relevance to the study question, reliability through consistent data collection and handling, and transparent analytical methods. If your data cannot pass those three tests with documented lineage, it is not ready for regulatory use.
How do clinical data lakehouses differ from traditional warehouses for RWE workloads?
Lakehouses combine the schema flexibility of a data lake with the governance and query structure of a warehouse. For RWE, that means you can ingest multi-modal data sources – EHRs, claims, registries, genomics – without rigid upfront schema design, while still enforcing the standards regulators and payers expect.
What should we ask potential clinical data platform partners about governance, not just features and price?
Ask specifically about data ownership after engagement ends, lineage documentation practices, alignment with current FDA RWE guidance, and incident response protocols for regulated data environments. Partners who cannot answer these questions clearly pose a governance risk, regardless of their technical capabilities.
